Signal
Novartis’ $2.9B MorphoSys Acquisition Hits Roadblock as Safety Concerns Delay Approval Filing
Novartis, MorphoSys, safety signal, delayed approval, biotech, pharmaceuticals
Lonza closes plant in China but CDMO’s sales signal an uptick in industry
Plants, China, Signal, Industry, Congestive heart failure